SCHEMBL6184720

SCHEMBL6184720

Fc1ccc(-c2nn3c(Cl)cc(Cl)cc3c2-c2ccnc(Nc3ccccc3)n2)cc1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 20/20 0.65
CDK2 P24941 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6182823 0.86 GSK3B (0.59) GSK3BCDK2
SCHEMBL6069213 0.86 GSK3B (0.65) GSK3BCDK2
SCHEMBL6184717 0.84 GSK3B (0.56) GSK3BCDK2
SCHEMBL5890649 0.81 CSNK1D (0.51) GSK3B
SCHEMBL4479248 0.79 GSK3B (1.00) GSK3BCDK2
Gw833373X SCHEMBL4480568 0.77 GSK3B (1.00) GSK3BCDK2
SCHEMBL6183945 0.77 GSK3B (0.61) GSK3BCDK2
SCHEMBL5453810 0.76 GSK3B (0.59) GSK3BCDK2
SCHEMBL5890227 0.76 CSNK1D (0.49) GSK3B
Gw829055X SCHEMBL4489350 0.75 GSK3B (1.00) GSK3BCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341788-B1 PYRAZOLOPYRIDINES GLAXO GROUP LTD (GB) 2005-08-10 EP disclosed
US-6919352-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-07-19 US disclosed
US-20040072853-A1 Therapeutic compounds CHAMBERLAIN STANLEY D (US) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072853-A1 Therapeutic compounds PCSK9, ABCB1, FURIN GSK3B 1270/4885CDK2 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.